Abstract
Compounds that inhibit the catalytic activity of cyclic nucleotide phosphodiesterases are used as therapeutic agents to increase intracellular cAMP and/or cGMP content in cells or tissues of interest. In patients with heart failure, inhibitors of enzymes in the PDE3 family of cyclic nucleotide phosphodiesterases are used to raise intracellular cAMP content in cardiac muscle, with inotropic actions. These drugs are effective in acute applications, but their long-term use has been complicated by an increase in cardiovascular mortality in clinical trials. Inhibitors of enzymes in the PDE5 family have been used to raise cGMP content in cardiac muscle in animal models of pressure overload, chronic β-adrenergic receptor stimulation, ischemic injury, and doxorubicin toxicity, and have been shown to have antihypertrophic and cardioprotective actions. Recent experimental results raise some question as to the likely applicability of these findings to humans, in whose hearts PDE5 is present at much lower levels than those seen in animal models, and raise the possibility of PDE1, a dual-specificity phosphodiesterase present at high levels in human myocardium, as an alternative target for inotropic and cardioprotective actions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Amsallem E, Kasparian C, Haddour G, Boissel JP, Nony P (2005) Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev 25:CD002230
Baim DS, McDowell AV, Cherniles J et al (1983) Evaluation of a new bipyridine inotropic agent – milrinone –in patients with severe congestive heart failure. N Engl J Med 309:748–756
Bender AT (2007) Calmodulin-stimulated cyclic nucleotide phosphodiesterases. In: Beavo JA, Francis SH, Houslay MD (eds) Cyclic nucleotide phosphodiesterases in health and disease. CRC Press, Boca Raton, FL, pp 35–54
Beuckelmann DJ, Nabauer M, Erdmann E (1992) Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 85:1046–1055
Bristow MR, Ginsburg R, Umans V et al (1986) Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 59:297–309
Choi YH, Ekholm D, Krall J et al (2001) Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes. Biochem J 353:41–50
Das A, Xi L, Kukreja RC (2005) Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 280:12944–12955
Das A, Xi L, Kukreja RC (2008) Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem 283:29572–29585
Das A, Salloum FN, Xi L, Rao YJ, Kukreja RC (2009) ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. Am J Physiol Heart Circ Physiol 296:H1236–H1243
Dieterle T, Meyer M, Gu Y et al (2005) Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure. Cardiovasc Res 67:678–688
Ding B, Abe J, Wei H et al (2005a) Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation 111:2469–2476
Ding B, Abe J, Wei H et al (2005b) A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci USA 102:14771–14776
Dorn GW 2nd (2009) Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling. Cardiovasc Res 81:465–473
Drakos SG, Kanakakis JV, Nanas S et al (2009) Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure. J Cardiovasc Pharmacol 53:157–161
Eizema K, Fechner H, Bezstarosti K et al (2000) Adenovirus-based phospholamban antisense expression as a novel approach to improve cardiac contractile dysfunction: comparison of a constitutive viral versus an endothelin-1-responsive cardiac promoter. Circulation 101:2193–2199
Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC (2005) Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111:1601–1610
Frace AM, Mery PF, Fischmeister R, Hartzell HC (1993) Rate-limiting steps in the beta-adrenergic stimulation of cardiac calcium current. J Gen Physiol 101:337–353
Francis SH, Corbin JD (2005) Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. Expert Opin Drug Metab Toxicol 1:283–293
Garlid KD, Costa AD, Quinlan CL, Pierre SV, Dos Santos P (2009) Cardioprotective signaling to mitochondria. J Mol Cell Cardiol 46:858–866
Hambleton R, Krall J, Tikishvili E et al (2005) Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium. J Biol Chem 280:39168–39174
Han SJ, Vaccari S, Nedachi T et al (2006) Protein kinase B/Akt phosphorylation of PDE3A and its role in mammalian oocyte maturation. EMBO J 25:5716–5725
Hassan MA, Ketat AF (2005) Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC Pharmacol 5:10
He H, Meyer M, Martin JL et al (1999) Effects of mutant and antisense RNA of phospholamban on SR Ca(2+)-ATPase activity and cardiac myocyte contractility. Circulation 100:974–980
Hoshijima M, Ikeda Y, Iwanaga Y et al (2002) Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 8:864–871
Iwanaga Y, Hoshijima M, Gu Y et al (2004) Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest 113:727–736
Jaski BE, Fifer MA, Wright RF, Braunwald E, Colucci WS (1985) Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J Clin Invest 75:643–649
Juhaszova M, Zorov DB, Kim SH et al (2004) Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113:1535–1549
Kass DA, Champion HC, Beavo JA (2007) Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 101:1084–1095
Kenan Y, Murata T, Shakur Y, Degerman E, Manganiello VC (2000) Functions of the N-terminal region of cyclic nucleotide phosphodiesterase 3 (PDE 3) isoforms. J Biol Chem 275:12331–12338
Lehnart SE, Wehrens XH, Reiken S et al (2005) Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 123:25–35
Lim SY, Davidson SM, Hausenloy DJ, Yellon DM (2007) Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore. Cardiovasc Res 75:530–535
Lin CS, Chow S, Lau A, Tu R, Lue TF (2002) Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters. Int J Impot Res 14:15–24
Liu Y, Sato T, O'Rourke B, Marban E (1998) Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation 97:2463–2469
Marx SO, Reiken S, Hisamatsu Y et al (2000) PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101:365–376
Meyer M, Belke DD, Trost SU et al (2004) A recombinant antibody increases cardiac contractility by mimicking phospholamban phosphorylation. FASEB J 18:1312–1314
Miller CL, Oikawa M, Cai Y et al (2009) Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ Res 105:956–964
Minamisawa S, Hoshijima M, Chu G et al (1999) Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99:313–322
Movsesian MA, Bristow MR (2005) Alterations in cAMP-mediated signaling and their role in the pathophysiology of dilated cardiomyopathy. Curr Top Dev Biol 68:25–48
Movsesian MA, Smith CJ, Krall J, Bristow MR, Manganiello VC (1991) Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest 88:15–19
Movsesian M, Stehlik J, Vandeput F, Bristow MR (2009) Phosphodiesterase inhibition in heart failure. Heart Fail Rev 14:255–263
Nagayama T, Zhang M, Hsu S, Takimoto E, Kass DA (2008) Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil. J Pharmacol Exp Ther 326:380–387
Nagayama T, Hsu S, Zhang M et al (2009) Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol 53:207–215
Nagendran J, Archer SL, Soliman D et al (2007) Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116:238–248
Nanas JN, Tsagalou EP, Kanakakis J et al (2004) Long-term intermittent dobutamine infusion, combined with oral amiodarone for end-stage heart failure: a randomized double-blind study. Chest 125:1198–1204
Nimer LR, Needleman DH, Hamilton SL, Krall J, Movsesian MA (1995) Effect of ryanodine on sarcoplasmic reticulum Ca2+ accumulation in nonfailing and failing human myocardium. Circulation 92:2504–2510
Ockaili R, Salloum F, Hawkins J, Kukreja RC (2002) Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol 283:H1263–H1269
Pokreisz P, Vandenwijngaert S, Bito V et al (2009) Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 119:408–416
Reiken S, Gaburjakova M, Guatimosim S et al (2003) Protein kinase A phosphorylation of the cardiac calcium release channel (ryanodine receptor) in normal and failing heartsRole of phosphatases and response to isoproterenol. J Biol Chem 278:444–453
Salloum F, Yin C, Xi L, Kukreja RC (2003) Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 92:595–597
Salloum FN, Abbate A, Das A et al (2008) Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol 294:H1398–H1406
Salloum FN, Chau VQ, Hoke NN et al (2009) Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide. Circulation 120:S31–S36
Sculptoreanu A, Rotman E, Takahashi M, Scheuer T, Catterall WA (1993) Voltage-dependent potentiation of the activity of cardiac L-type calcium channel alpha 1 subunits due to phosphorylation by cAMP-dependent protein kinase. Proc Natl Acad Sci USA 90:10135–10139
Shakur Y, Takeda K, Kenan Y et al (2000) Membrane localization of cyclic nucleotide phosphodiesterase 3 (PDE3). Two N-terminal domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum. J Biol Chem 275:38749–38761
Shimizu K, Shintani Y, Ding WG, Matsuura H, Bamba T (2002) Potentiation of slow component of delayed rectifier K(+) current by cGMP via two distinct mechanisms: inhibition of phosphodiesterase 3 and activation of protein kinase G. Br J Pharmacol 137:127–137
Simmerman HK, Jones LR (1998) Phospholamban: protein structure, mechanism of action, and role in cardiac function. Physiol Rev 78:921–947
Sinoway LS, Maskin CS, Chadwick B, Forman R, Sonnenblick EH, Le Jemtel TH (1983) Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease. J Am Coll Cardiol 2:327–331
Suckau L, Fechner H, Chemaly E et al (2009) Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 119:1241–1252
Takasago T, Imagawa T, Shigekawa M (1989) Phosphorylation of the cardiac ryanodine receptor by cAMP-dependent protein kinase. J Biochem (Tokyo) 106:872–877
Takimoto E, Champion HC, Li M et al (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11:214–222
Takimoto E, Belardi D, Tocchetti CG et al (2007) Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5. Circulation 115:2159–2167
Uretsky BF, Generalovich T, Reddy PS, Spangenberg RB, Follansbee WP (1983) The acute hemodynamic effects of a new agent, MDL 17, 043, in the treatment of congestive heart failure. Circulation 67:823–828
Vandecasteele G, Verde I, Rucker-Martin C, Donzeau-Gouge P, Fischmeister R (2001) Cyclic GMP regulation of the L-type Ca(2+) channel current in human atrial myocytes. J Physiol 533:329–340
Vandeput F, Wolda SL, Krall J et al (2007) Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes. J Biol Chem 282:32749–32757
Vandeput F, Krall J, Ockaili R et al (2009) cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther 330:884–891
Watanabe A, Arai M, Yamazaki M, Koitabashi N, Wuytack F, Kurabayashi M (2004) Phospholamban ablation by RNA interference increases Ca2+ uptake into rat cardiac myocyte sarcoplasmic reticulum. J Mol Cell Cardiol 37:691–698
Wechsler J, Choi YH, Krall J, Ahmad F, Manganiello VC, Movsesian MA (2002) Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes. J Biol Chem 277:38072–38078
Yan C, Miller CL, Abe J (2007) Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ Res 100:489–501
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Movsesian, M.A., Kukreja, R.C. (2011). Phosphodiesterase Inhibition in Heart Failure. In: Francis, S., Conti, M., Houslay, M. (eds) Phosphodiesterases as Drug Targets. Handbook of Experimental Pharmacology, vol 204. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-17969-3_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-17969-3_10
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-17968-6
Online ISBN: 978-3-642-17969-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)